Given that targeting Mcl-1, directly or indirectly, alone or combinatorial proved to be promising apoptosis-based anticancer therapeutic strategies13,17,18,27,28, we reckon that delineating the overlooked aspect is worthwhile and combination therapy based on such information may extend the application range and improve the performance of KPT-330 in cancer treatment. This evidence concerns the gene MCL1 and cancer.